Mast cell stabilizer, an anti-allergic drug, reduces ventricular arrhythmia risk via modulation of neuroimmune interaction

• DOI: 10.1007/s00395-023-01024-y
• Publication Date: 2024-01-03T20:03:02Z
• Authors: Yuhong Wang; Zhihao Liu; Wenjie Zhou; Jun Wang; Rui Li; Chen Peng; Liying Jiao; Song Zhang; Zhihao Liu; Zhongyang Yu; Ji Sun; Qiang Deng; Shoupeng Duan; Wuping Tan; Yijun Wang; Lingpeng Song; Fuding Guo; Zhen Zhou; Yueyi Wang; Liping Zhou; Hong Jiang; Lilei Yu
• Keywords: Stellate ganglion; Cardiac Electrophysiology

Mast cells (MCs) are important intermediates between the nervous and immune systems. The cardiac autonomic nervous system (CANS) crucially modulates cardiac electrophysiology and arrhythmogenesis, but whether and how MC-CANS neuroimmune interaction influences arrhythmia remain unclear. Our clinical data showed a close relationship between serum levels of MC markers and CANS activity, and then we use mast cell stabilizers (MCSs) to alter this MC-CANS communication. MCSs, which are well-known anti-allergic agents, could reduce the risk of ventricular arrhythmia (VA) after myocardial infarction (MI). RNA-sequencing (RNA-seq) analysis to investigate the underlying mechanism by which MCSs could affect the left stellate ganglion (LSG), a key therapeutic target for modulating CANS, showed that the IL-6 and γ-aminobutyric acid (GABA)-ergic system may be involved in this process. Our findings demonstrated that MCSs reduce VA risk along with revealing the potential underlying antiarrhythmic mechanisms.